138 related articles for article (PubMed ID: 36633913)
41. Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B.
Jeon MY; Kim BK; Lee JS; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Kim SU
Clin Mol Hepatol; 2021 Apr; 27(2):295-304. PubMed ID: 33317247
[TBL] [Abstract][Full Text] [Related]
42. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study.
Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH
J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102
[TBL] [Abstract][Full Text] [Related]
43. New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage.
Yin GQ; Li J; Zhong B; Yang YF; Wang MR
World J Gastroenterol; 2021 Feb; 27(8):666-676. PubMed ID: 33716446
[TBL] [Abstract][Full Text] [Related]
44. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
[TBL] [Abstract][Full Text] [Related]
45. Association of Virological Response to Antiviral Therapy With Survival in Intermediate-Stage Hepatitis B Virus-Related Hepatocellular Carcinoma After Chemoembolization.
Jin M; Chen Y; Hu S; Zhu M; Wang Y; Chen M; Peng Z
Front Oncol; 2021; 11():751777. PubMed ID: 34745980
[TBL] [Abstract][Full Text] [Related]
46. An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia.
Lee HW; Park SY; Lee M; Lee EJ; Lee J; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK
Liver Int; 2020 Jul; 40(7):1736-1743. PubMed ID: 32239602
[TBL] [Abstract][Full Text] [Related]
47. Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B.
Choi WM; Kim GA; Choi J; Han S; Lim YS
J Clin Invest; 2022 May; 132(10):. PubMed ID: 35358094
[TBL] [Abstract][Full Text] [Related]
48. Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation: A retrospective study based on Baveno VII criteria.
Zhang Y; Liu X; Li S; Lin C; Ye Q; Wang Y; Wu J; Zhang Y; Gao H; Li T; Qu Y; Wang Y
Hepatol Commun; 2024 Jan; 8(1):. PubMed ID: 38126951
[TBL] [Abstract][Full Text] [Related]
49. Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching.
Li T; Qu Y; Wang Y; Lin C; Yang B; Wang L
J Coll Physicians Surg Pak; 2019 Apr; 29(4):317-323. PubMed ID: 30925952
[TBL] [Abstract][Full Text] [Related]
50. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
51. Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B.
Chon HY; Seo YS; Lee JI; Kim BS; Jang BK; Kim SG; Suk KT; Kim IH; Lee JW; Chon YE; Kim MY; Jeong SW; Lee HA; Yim SY; Um SH; Lee HW; Lee KS; Song JE; Lee CH; Chung WJ; Hwang JS; Yoo JJ; Kim YS; Kim DJ; Lee CH; Yu JH; Ha YJ; Kim MN; Lee JH; Hwang SG; Kang SH; Baik SK; Jang JY; Suh SJ; Jung YK; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Yim HJ; Kim SU;
Eur J Gastroenterol Hepatol; 2021 Jun; 33(6):885-893. PubMed ID: 32541238
[TBL] [Abstract][Full Text] [Related]
52. Antiviral therapy improves post-operative survival outcomes in patients with HBV-related hepatocellular carcinoma of less than 3 cm - A retrospective cohort study.
Wang ZY; Tao QF; Wang ZH; Lin KY; Huang G; Yang Y; Zhou WP; Lau WY
Am J Surg; 2020 Apr; 219(4):717-725. PubMed ID: 31266631
[TBL] [Abstract][Full Text] [Related]
53. Antiviral therapy improves postoperative survival of patients with HBV-related hepatocellular carcinoma.
Guan RY; Sun BY; Wang ZT; Zhou C; Yang ZF; Gan W; Huang JL; Liu G; Zhou J; Fan J; Yi Y; Qiu SJ
Am J Surg; 2022 Jul; 224(1 Pt B):494-500. PubMed ID: 35115174
[TBL] [Abstract][Full Text] [Related]
54. Virologic response maintenance and hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir.
Wang X; Chen Y; Xu M; Cheng K; Duan X; Liao W; Wang Y; Lu Y; Duan Z; Wang L
Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1337-1344. PubMed ID: 34511012
[TBL] [Abstract][Full Text] [Related]
55. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.
Kim CH; Um SH; Seo YS; Jung JY; Kim JD; Yim HJ; Keum B; Kim YS; Jeen YT; Lee HS; Chun HJ; Kim CD; Ryu HS
J Gastroenterol Hepatol; 2012 Oct; 27(10):1589-95. PubMed ID: 22554121
[TBL] [Abstract][Full Text] [Related]
56. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
[TBL] [Abstract][Full Text] [Related]
57. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B.
Kim BG; Park NH; Lee SB; Jeon S; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
Liver Int; 2018 Dec; 38(12):2269-2276. PubMed ID: 30052303
[TBL] [Abstract][Full Text] [Related]
58. Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy.
Lin CL; Tseng KC; Chen KY; Liao LY; Kao JH
J Formos Med Assoc; 2020 Oct; 119(10):1483-1489. PubMed ID: 32653388
[TBL] [Abstract][Full Text] [Related]
59. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma.
Urata Y; Kubo S; Takemura S; Uenishi T; Kodai S; Shinkawa H; Sakae M; Kaneda K; Ohata K; Nozawa A; Suehiro S
J Hepatobiliary Pancreat Sci; 2012 Nov; 19(6):685-96. PubMed ID: 22203455
[TBL] [Abstract][Full Text] [Related]
60. Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase.
Lee HW; Kim EH; Lee J; Kim SU; Park JY; Kim DY; Ahn SH; Han KH; Kim BK
Clin Transl Gastroenterol; 2020 Mar; 11(3):e00140. PubMed ID: 32352711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
